Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung CancerBusiness Wire • 01/18/24
Wall Street Analysts Predict a 105.85% Upside in NovoCure (NVCR): Here's What You Should KnowZacks Investment Research • 01/11/24
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed GlioblastomaBusiness Wire • 01/09/24
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company UpdateBusiness Wire • 01/08/24
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to ProfitabilityBusiness Wire • 11/28/23
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual MeetingBusiness Wire • 11/10/23
Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023Business Wire • 10/15/23
Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research ProgramBusiness Wire • 10/12/23
Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual MeetingBusiness Wire • 09/29/23
Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung CancerBusiness Wire • 09/08/23